会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl-2-quinolinone derivatives
    • 法呢基蛋白转移酶抑制(咪唑-5-基)甲基-2-喹啉酮衍生物
    • US06420387B1
    • 2002-07-16
    • US09689211
    • 2000-10-12
    • Marc Gaston VenetPatrick René AngibaudPhilippe MullerGérard Charles Sanz
    • Marc Gaston VenetPatrick René AngibaudPhilippe MullerGérard Charles Sanz
    • A61K31445
    • C07D231/12C07D233/56C07D249/08C07D401/06C07D401/14C07D405/14C07D407/14C07D413/14Y02P20/55
    • This invention comprises the novel compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula —Alk1—C(═O)—R9, —Alk1—S(O)—R9 or —Alk1—S(O)2—R9; R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6akyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4 and R5 each independently are hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl; R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, 4,4-dimethyl-oxazolyl, C1-6alkyloxy or Ar2oxy; R8 is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonylC1-6alkyl; cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, carboxyC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, imidazolyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl, aminocarbonylC1-6alkyl, or a radical of formula —O—R10, —SR10, —N—R11R12; R17 is hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxycarbonyl, Ar1; R18 is hydrogen, C1-6alkyl, C1-6alkyloxy or halo; R19 is hydrogen or C1-6alkyl; having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.
    • 本发明包括式(I)的新化合物,其中虚线表示任选的键; X是氧或硫; R1是氢,C1-12烷基,Ar1,Ar2C1-6烷基,喹啉基C 1-6烷基,吡啶基C 1-6烷基,羟基C 1-6烷基,C 1-6烷氧基C 1-6烷基,一或二(C 1-6烷基)氨基C 1-6烷基,氨基C 1-6烷基或 式-Alk1-C(= O)-R9,-Alk1-S(O)-R9或-Alk1-S(O)2-R9的基团; R 2,R 3和R 16各自独立地是氢,羟基,卤素,氰基,C 1-6烷基,C 1-6烷氧基,羟基C 1-6烷氧基,C 1-6烷氧基C 1-6烷氧基,氨基C 1-6烷氧基,一或二(C 1-6烷基)氨基C 1-6烷氧基 Ar 1,Ar 2 C 1-6烷基,Ar 2氧基,Ar 2 C 1-6烷氧基,羟基羰基,C 1-6烷氧基羰基,三卤代甲基,三卤代甲氧基,C 2-6烯基; R 4和R 5各自独立地是氢,卤素,Ar 1,C 1-6烷基,羟基C 1-6烷基,C 1-6烷氧基C 1-6烷基,C 1-6烷氧基,C 1-6烷硫基,氨基,羟基羰基,C 1-6烷氧基羰基,C 1-6烷基S(O) C 1-6烷基或C 1-6烷基S(O)2 C 1-6烷基; R 6和R 7各自独立地为氢,卤素,氰基,C 1-6烷基,4,4-二甲基 - 恶唑基,C 1-6烷氧基或Ar 2氧基; R 8是氢,C 1-6烷基,氰基,羟基羰基,C 1-6烷氧基羰基,C 1-6烷基羰基C 1-6
    • 2. 发明授权
    • Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
    • 法呢基蛋白转移酶抑制(咪唑-5-基)甲基-2-喹啉酮衍生物
    • US06169096A
    • 2001-01-02
    • US09363353
    • 1999-07-29
    • Marc Gaston VenetPatrick Ren{acute over (e)} AngibaudPhilippe MullerG{acute over (e)}rard Charles Sanz
    • Marc Gaston VenetPatrick Ren{acute over (e)} AngibaudPhilippe MullerG{acute over (e)}rard Charles Sanz
    • A01N4342
    • C07D231/12C07D233/56C07D249/08C07D401/06C07D401/14C07D405/14C07D407/14C07D413/14Y02P20/55
    • This invention comprises the novel compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula —Alk1—C(═O)—R9, —Alk1—S(O)—R9 or —Alk1—S(O)2—R9; R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono-or di(C1-6alkyl)aminoC1-6alkyloxy,Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4 and R5 each independently are hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl; R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, 4,4-dimethyl-oxazolyl, C1-6alkyloxy or Ar2oxy; R8 is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonylC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, carboxyC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, imidazolyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl, aminocarbonylC1-6alkyl, or a radical of formula —O—R10, —S—R10, —N—R11R12; R17 is hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxycarbonyl, Ar1; R18 is hydrogen, C1-6alkyl, C1-6alkyloxy or halo; R19 is hydrogen or C1-6alkyl; having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.
    • 本发明包括式(I)的新化合物,其中虚线表示任选的键; X是氧或硫; R1是氢,C1-12烷基,Ar1,Ar2C1-6烷基,喹啉基C 1-6烷基,吡啶基C 1-6烷基,羟基C 1-6烷基,C 1-6烷氧基C 1-6烷基,一或二(C 1-6烷基)氨基C 1-6烷基,氨基C 1-6烷基或 式-Alk1-C(= O)-R9,-Alk1-S(O)-R9或-Alk1-S(O)2-R9的基团; R 2,R 3和R 16各自独立地为氢,羟基,卤素,氰基,C 1-6烷基,C 1-6烷氧基,羟基C 1-6烷氧基,C 1-6烷氧基C 1-6烷氧基,氨基C 1-6烷氧基,单 - 或二(C 1-6烷基)氨基C 1-6烷氧基 Ar 1,Ar 2 C 1-6烷基,Ar 2氧基,Ar 2 C 1-6烷氧基,羟基羰基,C 1-6烷氧基羰基,三卤代甲基,三卤代甲氧基,C 2-6烯基; R 4和R 5各自独立地为氢,卤素,Ar 1,C 1-6烷基,羟基C 1-6烷基,C 1-6烷氧基C 1-6烷基,C 1-6烷氧基,C 1-6烷硫基,氨基,羟基羰基,C 1-6烷氧基羰基,C 1-6烷基S(O) C 1-6烷基或C 1-6烷基S(O)2 C 1-6烷基; R 6和R 7各自独立地为氢,卤素,氰基,C 1-6烷基,4,4-二甲基 - 恶唑基,C 1-6烷氧基或Ar 2氧基; R 8是氢,C 1-6烷基,氰基,羟基羰基,C 1-6烷氧基羰基,C 1-6烷基羰基C 1-6
    • 6. 发明申请
    • 2-SUBSTITUTED BENZIMIDAZOLES
    • US20100092426A1
    • 2010-04-15
    • US11993136
    • 2006-06-20
    • Jean-Francois BonfantiPhilippe MullerJérôme Michel Claude FortinFrédéric Marc Maurice Doublet
    • Jean-Francois BonfantiPhilippe MullerJérôme Michel Claude FortinFrédéric Marc Maurice Doublet
    • C07D401/06C07D413/14A61K31/5377A61K31/4439A61P31/12A61K38/21A61K38/19
    • C07D401/06C07D235/30
    • Inhibitors of RSV replication of formula (I) the addition salts and stereochemically isomeric forms thereof, wherein Q is hydrogen, C1-6alkyl optionally substituted with a heterocycle or Q is C1-6alkyl substituted with both —OR4 and a heterocycle; wherein said heterocycle is oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydro-thiazepine, 1-oxo-hexahydrothiazepine, 1,1-dioxo-hexahydrothiazepine, pyrrolidine, piperidine, homopiperidine, piperazine; which heterocyle may be substituted with 1-2 substituents; each Alk is C1-6alkanediyl; R1 is Ar2 or optionally substituted piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydro-furanyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyridinyl or 2,3-dihydro-1,4-dioxino[2,3-b]pyridyl; R3 is hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, cyanoC1-6alkyl, aminocarbonyl-C1-6-alkyl, mono- or di(C1-6alkyl)aminocarbonyl-C1-6-alkyl, carboxyl-C1-6-alkyl, C1-6alkoxycarbonyl-C1-6alkyl; R2 is hydrogen or C1-6alkyl; R3 and R4 are hydrogen, C1-6alkyl, Ar2, Ar2C1-6alkyl, C1-6alkylcarbonyl, Ar2carbonyl, Ar2C1-6alkylcarbonyl, C1-6alkylsulfonyl, aminosulfonyl, Ar1sulfonyl, Ar1C1-6alkylsulfonyl, C1-6alkyloxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)-aminoC1-6alkyl, hydroxyC1-6alkyl, aminocarbonylC1-6alkyl, C1-4alkyloxycarbonyl-C1-6alkyl, hydroxycarbonylC1-6alkyl, aminosulfonylC1-6alkyl, Het, Het-C1-6alkyl, Het-carbonyl, Het-sulfonyl, HetC1-6alkylsulfonyl, Het-C1-6alkylcarbonyl; Het is an optionally substituted heterocycle; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I).
    • 8. 发明授权
    • Photoreactive compounds and compositions
    • 光反应性化合物和组合物
    • US07928097B2
    • 2011-04-19
    • US11674183
    • 2007-02-13
    • Peter J. SadlerPhilippe Muller
    • Peter J. SadlerPhilippe Muller
    • A61K31/555C07F15/00
    • A61K33/24A61K31/28A61K31/555C07F15/0093
    • The present invention provides a compound of formula (I): PtIV(N3)2X1X2Y1Y2, wherein X1 and X2 are the same or different and each one is a group NR1R2R3 wherein R1, R2 and R3 are the same or different and each can be any one of H and optionally substituted alkyl, aryl, aralkyl, acyl, cycloalkyl, heterocyclyl, alkenyl, aralkenyl, alkinyl, cycloalkenyl, or X1 and X2 together represent a group R1R2NR4NR1R2 wherein R1 and R2 have the same meaning as before, and R4 represents an optionally substituted divalent, saturated or unsaturated, alkyl chain, an optionally substituted divalent, saturated or unsaturated cycloalkyl or an optionally substituted divalent aryl, or R4 or two or more of R1, R2, R3 and R4 and the respective N atom(s) to which they are linked, represent an optionally substituted heterocyclyl having at least one ring containing said N atom(s); and Y1 and Y2 are the same or different or when cis together represent a divalent moiety Y3, wherein at least one of Y1 and Y2, or Y3, is a substantially labile ligand in the analogous Pt(II) complex without the azide groups, whilst being substantially resistant, in vivo, to hydrolysis and physiological reducing agents. One or more of R1, R2, R3 and R4, may further represent a covalently bonded link to at least one further complex of formula (I) to form a dimer or oligomer, or to a targeting moiety having affinity for a predetermined tissue or cell type.
    • 本发明提供了式(I)的化合物:PtIV(N3)2X1X2Y1Y2,其中X1和X2相同或不同,并且每个是NR1R2R3基团,其中R1,R2和R3相同或不同,并且各自可以是任何 H和任选取代的烷基,芳基,芳烷基,酰基,环烷基,杂环基,烯基,芳烯基,炔基,环烯基或X1和X2之间的一个表示R1R2NR4NR1R2基团,其中R1和R2具有与之前相同的含义,R4代表 任选取代的二价,饱和或不饱和的烷基链,任选取代的二价,饱和或不饱和的环烷基或任选取代的二价芳基,或R 4或两个或多个R 1,R 2,R 3和R 4以及相应的N原子 它们相连,表示具有至少一个含有所述N原子的环的任选取代的杂环基; 并且Y1和Y2相同或不同,或者当顺式一起代表二价基团Y 3时,其中Y 1和Y 2或Y 3中的至少一个是没有叠氮基的类似Pt(II)络合物中基本不稳定的配体,而 在体内基本上抵抗水解和生理还原剂。 R 1,R 2,R 3和R 4中的一个或多个可以进一步代表与至少一个另外的式(I)配合物共价键合的连接以形成二聚体或寡聚体,或者与对预定组织或细胞具有亲和性的靶向部分 类型。
    • 9. 发明申请
    • PHOTOREACTIVE COMPOUNDS AND COMPOSITIONS
    • US20070142466A1
    • 2007-06-21
    • US11674183
    • 2007-02-13
    • Peter SadlerPhilippe Muller
    • Peter SadlerPhilippe Muller
    • A61K31/282C07F15/00
    • A61K33/24A61K31/28A61K31/555C07F15/0093
    • The present invention provides a compound of formula (I): PtIV(N3)2X1X2Y1Y2, wherein X1 and X2 are the same or different and each one is a group NR1R2R3 wherein R1, R2 and R3 are the same or different and each can be any one of H and optionally substituted alkyl, aryl, aralkyl, acyl, cycloalkyl, heterocyclyl, alkenyl, aralkenyl, alkinyl, cycloalkenyl, or X1 and X2 together represent a group R1R2NR4NR1R2 wherein R1 and R2 have the same meaning as before, and R4 represents an optionally substituted divalent, saturated or unsaturated, alkyl chain, an optionally substituted divalent, saturated or unsaturated cycloalkyl or an optionally substituted divalent aryl, or R4 or two or more of R1, R2, R3 and R4 and the respective N atom(s) to which they are linked, represent an optionally substituted heterocyclyl having at least one ring containing said N atom(s); and Y1 and Y2 are the same or different or when cis together represent a divalent moiety Y3, wherein at least one of Y1 and Y2, or Y3, is a substantially labile ligand in the analogous Pt(II) complex without the azide groups, whilst being substantially resistant, in vivo, to hydrolysis and physiological reducing agents. One or more of R1, R2, R3 and R4, may further represent a covalently bonded link to at least one further complex of formula (I) to form a dimer or oligomer, or to a targeting moiety having affinity for a predetermined tissue or cell type.